Skip to main content

Table 1 Participant characteristics

From: Gadolinium free cardiovascular magnetic resonance with 2-point Cine balanced steady state free precession

Variable Healthy Control (Group I) CVD without Enhancement (Group II) CVD with Enhancement (Groups III, IV) p-value
(n = 10) (n = 24) (n = 23)
Demographics     
 Age (yrs) 51.74 ± 4.7 47.7 ± 16.5 51.39 ± 15.4 .406
 BMI (kg/m2) 23.32 ± 1.5 29.3 ± 6.7 27.4 ± 3.6 .007
 Female 4 (50.0) 8 (33.3) 4 (17.4) .315
 White 9 (90.0) 20 (83.3) 18 (78.3) .815
 African American 0 3 (12.5) 3 (13.0) 1.00
 Hispanic or Other Race 1 (10.0) 1 (4.2) 2 (8.7) .051
CMR Indication     
 Cardiomyopathy   7 (29.2) 10 (43.5) .371
 Hypertrophic Cardiomyopathy   2 (8.3) 1 (4.3) 1.000
 Pericarditis, Myocarditis   2 (8.3) 2 (8.7) 1.000
 Sarcoidosis   2 (8.3) 2 (8.7) 1.000
 Syncope   4 (16.7) 0 .109
 Viability   3 (12.5) 5 (21.1) .461
 Other   4 (16.7) 3 (17.4) 1.000
Diagnosis     
 Ischemic Cardiomyopathy   4 (16.7) 10 (43.5) .060
 Non-Ischemic Cardiomyopathy   10 (41.7) 7 (30.4) .547
 Hypertrophic Cardiomyopathy   0 2 (8.7) .234
 No Evidence of Cardiomyopathy   8 (33.3) 0 .416
 Other   2 (8.3) 4 (17.4) .416
Ejection Fraction (%)   50.13 ± 14.4 42.57 ± 14.6 .081
End Diastolic Volume (mL)   190.6 ± 76.0 217.65 ± 81.1 .244
  1. CVD without Enhancement: Patients referred for CMR not demonstrating LGE enhancement in imaged slice
  2. CVD with Enhancement: Patients referred for CMR demonstrating LGE enhancement in imaged slice
  3. BMI: Body Mass Index (kg/m2)